Uncertainty and perception of danger among patients undergoing treatment for prostate cancer by Kazer, Meredith Wallace et al.
BJUI
B J U  I N T E R N A T I O N A L
 ©  2 0 1 2  T H E  A U T H O R S
E 8 4  B J U  I N T E R N A T I O N A L  ©  2 0 1 2  B J U  I N T E R N A T I O N A L  |  111 ,  E 8 4 – E 9 1  |  doi:10.1111/j.1464-410X.2012.11439.x
 What ’ s known on the subject? and What does the study add? 
 Marked differences in uncertainty among patients have been found relating to race 
and social environment indicating that as uncertainty increases, social functioning 
declines. Correlations have been found between uncertainty and patients ’ coping, 
psychological adjustment and perceptions of their health and illness. Studies suggest 
the detrimental effect of uncertainty among patients with prostate cancer in the 
perception of their quality of life. These studies underline the potential benefi t of 
targeted intervention. 
 The study provides a unique insight into the impact of uncertainty and perception of 
danger on overall satisfaction with treatment outcomes in men with prostate cancer. 
Its results suggest that possible disparities related to patient racial background and 
education may exist in the perception of cancer-related uncertainty. Racial and 
educational disparities, coupled with a mild to moderate association of uncertainty or 
danger perception and overall outcome satisfaction, suggest an unmet need for 
healthcare and nursing services for men undergoing treatment for prostate cancer. 
 OBJECTIVES 
 •  To investigate patient uncertainty and 
perception of danger regarding prospects 
for clinical prostate cancer control. 
 •  To determine the impact of these factors 
on satisfaction with overall prostate cancer 
treatment outcome. 
 PATIENTS AND METHODS 
 •  Men who had undergone primary 
treatment for early stage prostate cancer 
and who were participants in the Prostate 
Cancer Outcomes and Satisfaction with 
Treatment Quality Assessment (PROSTQA) 
prospective cohort study of prostate cancer 
outcomes (the parent study) were offered 
the opportunity to participate in the 
present study. 
 •  Centralized phone interviews were 
conducted to determine patient-reported 
uncertainty regarding cancer status 
(measured by the Mishel Uncertainty in 
Illness Scale-Community Form), perception 
of danger (measured by Folkman and 
Lazarus ’ Appraisal Scale) and satisfaction 
with treatment outcome (measured by the 
Service Satisfaction Scale for Cancer Care). 
The study used the same centralized 
telephone interview centre as was used in 
the parent study. 
 •  Data were collected at 48, 60 or 72 
months after the completion of prostate 
cancer treatment. 
 •  Relationships among measures were 
characterized by Spearman rank correlation 
coeffi cients ( r ). 
 RESULTS 
 •  A total of 338 agreed to participate, 
representing 76% of those who were 
invited. 
 •  Younger patients experienced less 
uncertainty ( r  = 0.20,  P  < 0.001), yet 
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 INTRODUCTION AND BACKGROUND 
 Prostate cancer is a major health problem 
for men. With  ∼ 217  730 new cases reported 
in the USA in 2010, it is the most commonly 
diagnosed cancer in US men  [ 1 ] . It is 
estimated that one in six men will be 
diagnosed with prostate cancer during his 
lifetime, and about one in 36 will die from 
the disease. The role of uncertainty as a 
determinant of the state of health of a 
patient with prostate cancer was originally 
described using the conceptual framework 
proposed by Mishel  [ 2 ] . The importance of 
uncertainty among prostate cancer survivors 
has been further explored in recent studies, 
suggesting that the impact of uncertainty 
on a cancer survivor ’ s health state is 
mediated by their appraisal of danger  [ 3,4 ] ; 
however, the impact of freedom from 
recurrence as compared with PSA relapse 
(after primary treatment for prostate cancer) 
on the appraisal of danger, and mediation of 
uncertainty by perception of danger on a 
patient ’ s overall state of health, has not 
been suffi ciently characterized. Moreover, 
the impact of uncertainty and perception of 
danger on overall cancer treatment outcome 
satisfaction has not been evaluated  [ 5 ] . 
 Uncertainty in illness is defi ned as a 
cognitive state resulting from insuffi cient 
cues with which a patient might form a 
cognitive schema or meaning of a situation 
or event  [ 6 ] . Prostate cancer, appraised as 
either a danger or an opportunity, may have 
an impact on a patient ’ s uncertainty and 
consequently satisfaction with his treatment 
outcome. The aims of the present study 
were to characterize patient, cancer and 
treatment factors that have an impact on 
uncertainty, perceived danger and 
satisfaction of outcome in men with 
localized prostate cancer and to evaluate the 
impact of uncertainty and the potential 
mediation of perceived danger upon overall 
outcome satisfaction. 
 Germino  et  al.  [ 7 ] evaluated the role of 
uncertainty in determining quality of life in 
men with localized prostate cancer and their 
families. The researchers compared baseline 
demographics, measurement of uncertainty, 
and quality of life outcomes among 140 
men who underwent surgery, 35 men 
treated by external beam radiation therapy 
and 26 men who chose watchful waiting. 
After controlling for age and education, the 
authors found no differences in levels of 
uncertainty among the different treatment 
groups, but they reported marked 
differences in uncertainty related to race 
and social environment with resultant 
worsening social functioning associated 
with increasing uncertainty. Small but 
signifi cant correlations were noted between 
uncertainty and patients ’ coping, 
psychological adjustment and perceptions of 
their health and illness. Correlates of 
uncertainty included perceptions about the 
quality of medical care, treatment and 
satisfaction with care. The small sample size 
in their study precluded strong conclusions 
regarding the presence and associations 
with uncertainty within each treatment 
group after stratifying by race; however this 
research identifi ed strong cultural 
associations with perceptions of uncertainty 
and their role in perceptions of quality of 
life in men with localized prostate cancer. 
 Payment  [ 8 ] found that men receiving 
hormone therapy for prostate cancer 
reported greater uncertainty than did men 
treated with radical prostatectomy. The 
investigator suggested that the fi ndings 
might be explained by the belief that 
surgical intervention implies cure, whereas 
hormone therapy is designed to halt disease 
spread temporarily. The experience of 
uncertainty may be more apparent as 
one ’ s illness becomes more serious or 
complex because of longer hospitalization, 
complex or experimental treatment regimens 
and mixed messages from healthcare 
providers. 
 Mishel  et  al.  [ 9 ] completed two large trials 
assessing an intervention to counter 
uncertainty in men with both localized 
disease ( n  = 239) and advanced prostate 
cancer ( n  = 271). They documented the 
negative effects of illness uncertainty on 
quality of life and the benefi t of an 
uncertainty management intervention to 
better manage incontinence and to provide 
better sexual functioning. In the second 
study of men with advanced or recurrent 
disease, intervention subjects reported less 
severe back pain, fewer problems with 
constipation, and an improved ability to get 
and maintain an erection. These studies 
suggest the detrimental effect of 
uncertainty in perception of quality of life 
among patients with prostate cancer and 
underline the potential benefi t of targeted 
intervention. 
 PATIENTS AND METHODS 
 PATIENTS 
 The Prostate Cancer Outcomes and 
Satisfaction with Treatment Quality 
Assessment (PROSTQA) study is a 
prospective, longitudinal, multicentre cohort 
reported greater perception of danger 
( r  =  − 0.12;  P  = 0.03) concerning their 
previously treated prostate cancer. 
 •  African-American patients showed 
greater uncertainty than other ethnic 
groups ( P  = 0.005) but did not have a 
greater perception of danger ( P  = 0.36). 
 •  Education played a major role in 
uncertainty; patients with lower levels of 
education tended to report higher degrees 
of uncertainty ( r  =  − 0.25;  P  < 0.001). 
 •  There was a mild to moderate general 
association between the three outcomes. A 
greater sense of uncertainty was associated 
with a greater perception of danger 
( r  = 0.34,  P  < 0.001), and as danger and 
uncertainty increased, satisfaction with 
treatment outcome tended to decrease 
( r was between  − 0.30 and  − 0.34,  P  < 0.001). 
 CONCLUSIONS 
 •  Results suggest that possible disparities 
related to patient racial background and 
education may exist in the perception of 
cancer-related uncertainty. 
 •  Racial and educational disparities, 
coupled with a mild to moderate 
association of uncertainty or danger 
perception and overall outcome 
satisfaction, suggest an unmet need 
for healthcare and nursing services for 
men undergoing treatment for prostate 
cancer. 
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comprising men with previously untreated 
clinical stage T1 to T2 prostate cancer who 
elected to undergo prostatectomy, 
brachytherapy, or external beam 
radiotherapy as primary treatment. They 
were enrolled from 2003 to 2006 at nine US 
university-affi liated hospitals, using an 
institutional review board-approved 
protocol, after providing written informed 
consent  [ 5 ] . All patients with an active 
PROSTQA follow-up interview over a 
6-month period were eligible for the 
present study, except those enrolled at 
UCLA and the University of Michigan-
Providence. These 517 patients were at 
their 48, 60, or 72 month PROSTQA 
follow-up interview and were asked to 
consent after answering PROSTQA questions. 
Of these 517 patients, a total of 444 
patients were asked to participate, of whom 
338 (76%) patients consented and 106 
patients declined, 52 patients were not 
reached for the interview and 21 declined 
further study participation before being 
asked. The present study added the Mishel 
Uncertainty in Illness Scale (MUIS-A) and 
Folkman and Lazarus ’ Appraisal Scale (to 
assess perception of danger) as instruments 
after patients had undergone the PROSTQA 
interview. 
 Potential participants who met eligibility 
criteria were identifi ed from the pool of 
patients participating in the parent PROSTQA 
cohort study. PROSTQA participants were 
asked for written formal consent to 
participate in research related to their 
treatment for prostate cancer. At the time of 
the 48- or 60- or 72-month telephone 
interview for data collection for the parent 
study, participants were invited to 
participate in the present companion 
research study, evaluating the uncertainty 
and danger that they perceived related to 
their prostate cancer health. Those patients 
who gave consent to participate had the 
uncertainty and danger appraisal questions 
administered as part of their regular 
interview for the parent study. Pilot testing 
of these additional questions at the 
computer assisted telephone interview (CATI) 
test centre has indicated that they took an 
additional 10 – 12  min to complete. To ensure 
uniformity in data collection, data were 
collected by the same centralized telephone 
interview centre used by the parent study. 
Supervisory staff at the interview centre 
monitored the interview process for 
adherence to protocol. 
 INSTRUMENTS 
 The domains of danger, uncertainty and 
satisfaction with treatment outcome were 
assessed using the MUIS-Community Form 
(MUIS-C), Folkman and Lazarus ’ Appraisal 
Scale, and fi ve questions from the Service 
Satisfaction Scale for Cancer Care (SCA). A 
higher score in each instrument, respectively, 
refl ects an increase in perceived uncertainty, 
perceived danger and satisfaction with 
treatment outcome. 
 The 23-item MUIS-C uses a 5-point Likert 
scale (1  = strongly disagree; 5  = strongly 
agree) modifi ed from the 33-item MUIS-A. 
The MUIS-C is intended for use with 
community-dwelling chronically ill adults 
who may or may not be receiving treatment. 
Although the validity of the MUIS-C has not 
been directly measured, its items are highly 
similar to those of the original MUIS-A and 
the validity results from that instrument 
have been used to support the MUIS-C  [ 10 ] . 
 Folkman and Lazarus ’ Appraisal Scale  [ 11 ] 
consists of 15 questions, on a 5-point Likert 
scale (0  = not at all; 5  = a great deal) for a 
possible total of 75 points. Respondents are 
asked to rate the extent to which they felt 
each of 15 emotions regarding a stressor, in 
the present case prostate cancer or its 
treatment side effects; eight questions 
pertain to perceived danger and the others 
to perceived opportunity. The sum of the 
chosen numerical values give a fi nal 
opportunity and danger appraisal score. 
Previous research  [ 3 ] has shown that the 
addition of  ‘ danger ’ in the prostate cancer 
population signifi cantly increased the 
variance in quality of life above and beyond 
uncertainty, underscoring the emphasis of 
danger in this research. 
 The fi ve SCA questions that addressed 
satisfaction with treatment outcome were 
on the following areas: (i) the effect of 
health care services; (ii) the effect of 
treatment on cancer progression; (iii) the 
quality of cancer care; (iv) the effect of 
services; and (v) overall satisfaction with 
treatment. The mean scores from the fi ve 
questions provide a score ranging from 0 to 
100  [ 12 ] . 
 No instrument guidelines could be found on 
how to handle missing item responses in 
the MUIS-C and the danger appraisal scale. 
Case mean substitution as described by 
Fox-Wasylyshyn and El-Masri  [ 13 ] and 
Fayers  et  al.  [ 14 ] was used to impute 
missing item responses separately for each 
instrument. If a patient responded to at 
least half the domain ’ s questions, the mean 
of the other responses was used to impute 
missing responses. Nine of 338 patients who 
consented to the present study either did 
not respond to at least half the uncertainty 
or half the danger domain questions. 
 Further imputation using the satisfaction 
with treatment outcome score beyond that 
which was carried out in the PROSTQA 
parent study was not performed. In that 
study, a satisfaction with treatment outcome 
score was obtained as long as four of fi ve 
questions on the survey were answered. 
Only one patient did not answer at least 
four questions. A description of this and the 
other nine patients with an insuffi cient 
number of uncertainty or danger domain 
responses are shown in  Table  1 as patients 
who consented to the present study but did 
not complete the interviews. 
 As a sensitivity check, conclusions did not 
change when imputing the lowest and the 
highest possible response for each 
unanswered question. The one exception 
was that the univariate effect of planned 
treatment upon perceived danger loses its 
signifi cance when assuming either the 
minimum or maximum item response; 
however, the effect of planned treatment 
upon danger may, in the fi rst place, be more 
refl ective of age and other demographics of 
each planned treatment type. 
 STATISTICAL ANALYSIS 
 A Fisher ’ s exact test, and  ANOVA in the case 
of body mass index, was used to test for 
demographic differences among those 
analysed, those who consented but were 
unanalysable, and those who declined 
consent ( Table  1 ). Spearman rank 
correlations were used to summarize which 
continuous characteristics (such as age at 
baseline) were associated with increased 
outcomes of perception of danger, 
uncertainty, and satisfaction with treatment 
outcome; associations of categorical 
characteristics (such as education level) to 
these outcomes were tested by linear 
regression with outcomes estimated by 
generalized estimating equations (GEEs), and 
the Kruskal – Wallis Test in the case of 
variables with sparse cells ( Table  2 ). Because 
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 TABLE  1  Characteristics of PROSTQA participants approached for Uncertainty study *  
Demographic
Consented  – completed 
interviews ( n  =  328)
Consented  – did not 
complete interviews ( n  =  10)
Declined consent 
( n  =  106)  P value † 
Year of follow-up when approached for uncertainty  – no. (%) 0.74
  48 month interview 95 (29) 1 (10) 30 (28)
  60 month interview 84 (26) 4 (40) 27 (26)
  72 month interview 149 (45) 5 (50) 49 (46)
Age 0.32
  Median  – yr 64 71 64
  Range  – yr 45 – 80 58 – 75 47 – 85
  Age group  – no. (%)
   < 60  yr 100 (30) 1 (10) 31 (29)
   60 – 69  yr 134 (41) 3 (30) 40 (38)
   > 69  yr 94 (29) 6 (60) 35 (33)
Race  – no. (%) ‡ 0.22
  White 299 (91) 0 (0) 88 (83)
  African American 23 (7) 10 (100) 15 (14)
  Other 2 (1) 0 (0) 1 (1)
  Not reported 4 (1) 0 (0) 2 (2)
Education level at baseline  – no. (%) 0.94
  < HS graduate 6 (2) 0 (0) 4 (4)
  HS graduate 59 (18) 1 (10) 18 (17)
  Some college 75 (23) 2 (20) 27 (25)
  College graduate 69 (21) 2 (20) 21 (20)
  Grad school 119 (36) 5 (50) 36 (34)
Married or with partner  – no (%) § 284 (87) 10 (100) 89 (84) 0.54
Any coexisting illnesses  – no. (%) 75 (23) 2 (20) 25 (24) 0.97
Mean body-mass index  – no. (%) 28.1  ±  4.3 30.6  ±  3.7 28.0  ±  5.0 0.23
PSA 0.38
  Median  – ng/ml 5.4 5.1 5.5
  Range  – ng/ml 0.5 – 54.0 3.0 – 7.1 1.2 – 30.7
  Group  – no. (%)
   < 4  ng/mL 66 (20) 4 (40) 21 (20)
   4 – 10  ng/mL 217 (66) 6 (60) 75 (71)
   > 10  ng/mL 45 (14) 0 (0) 10 (9)
Gleason score on biopsy  – no. (%) 0.63
  < 7 182 (55) 5 (50) 64 (60)
  7 130 (40) 5 (50) 35 (33)
  > 7 16 (5) 0 (0) 7 (7)
Clinical stage  – no. (%) 0.004
  T1 232 (71) 7 (70) 91 (86)
  T2 96 (29) 3 (30) 15 (14)
Overall cancer severity  – no. (%) ¶ 0.64
  Low risk 160 (49) 5 (50) 60 (57)
  Intermediate risk 142 (43) 5 (50) 38 (36)
  High risk 26 (8) 0 (0) 8 (7)
Planned treatment  – no. (%) 0.97
  Radical prostatectomy 158 (48) 5 (50) 55 (52)
  External radiation therapy 89 (27) 3 (30) 27 (25)
  Brachytherapy 81 (25) 2 (20) 24 (23)
Planned neoadjuvant hormonal therapy  – no. (%) 36 (11) 0 (0) 10 (9) 0.70
 * Plus-minus values are means  ±  SD . A higher score refl ects an increase in perceived danger, perceived uncertainty, and Satisfaction with Treatment Outcome.  † Fisher ’ s 
exact test between those who accepted and completed the interviews; those who accepted but did not complete the interviews; and those who declined participation in 
the Uncertainty Study; BMI tested with  ANOVA .  ‡ Four individuals who accepted participation did not self-report race.  § One individual who accepted participation did not 
self-report marriage/living with partner status.  ¶ Risk defi ned by D’Amico Risk Level. Low Risk, PSA  ≤  10  & Gleason Score  <  7  & Stage  =  T1 or T2a. High Risk, PSA  >  20 or 
Gleason Score  >  7 or Stage  ≥  T2c. Intermediate Risk, All else. 
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 TABLE  2  Association of participant characteristics with perception of danger, uncertainty and satisfaction of treatment outcome 
Demographic
Danger Uncertainty
Satisfaction with treatment 
outcome
Correlation/Median 
(Q1,Q3)  P * 
Correlation/Mean 
( SD )  P * 
Correlation/Median 
(Q1,Q3)  P * 
All Time since treatment 1 (0, 4)  – 42.3 (13.4)  – 93 (83, 100)  – 
  Spearman rank correlation  − 0.02 0.66 0.06 0.30 0.02 0.69
  Follow-up stage when approached for participation 
in the present study
0.92 0.18 0.24
   48-month interview 2 (0, 4) 41.1 (11.7) 90 (83, 100)
   60-month interview 1 (0, 4) 40.9 (13.3) 93 (83, 100)
   72-month interview 1 (0, 6) 43.8 (14.4) 93 (83, 100)
Age at treatment
  Spearman rank correlation  − 0.12 0.03 0.20  < 0.001  − 0.03 0.64
  Age group 0.22 0.006 0.13
   < 60 years 2 (0, 6) 39.3 (12.8) 97 (83, 100)
   60 – 69 years 1 (0, 5) 42.1 (12.6) 90 (83, 100)
   > 69 years 0 (0, 3) 45.8 (14.5) 95 (83, 100)
Race/Ethnicity 0.36 0.005 0.79
  White 1 (0, 5) 41.6 (13.2) 93 (83, 100)
  African-American 2 (0, 4) 51.7 (13.6) 97 (83, 100)
  Other 0 (0, 0) 42.0 (5.7) 95 (90, 100)
  Not reported 1 (0, 2) 42.0 (12.1) 90 (83, 98)
Education level at treatment
  Spearman rank correlation 0.00 0.93  − 0.25  < 0.001 0.03 0.61
  Level of education 0.25  < 0.001 0.63
   < High school graduate 1 (0, 4) 49.8 (6.7) 92 (86, 100)
   High school graduate 1 (0, 4) 47.5 (14.5) 97 (83, 100)
   Some college education 2 (0, 6) 43.9 (13.3) 90 (83, 100)
   College graduate 1 (0, 4) 40.9 (13.3) 90 (83, 100)
   Graduation school 1 (0, 5) 39.1 (12.2) 93 (83, 100)
Married or with partner 0.13 0.94 0.51
  No 0 (0, 3) 44.0 (17.8) 93 (83, 100)
  Yes 2 (0, 5) 42.0 (12.7) 93 (83, 100)
  Not reported 8 (8, 8) 40.0 † 100 (100, 100)
Coexisting illnesses at treatment
  Spearman rank correlation  − 0.04 0.50 0.04 0.47 0.05 0.39
  Presence of coexisting illnesses 0.36 0.89 0.06
  No 1 (0, 4) 42.2 (13.2) 93 (83, 100)
  Yes 1 (0, 5) 42.5 (14.0) 90 (83, 100)
Planned treatment 0.05 0.82 0.05
  Radical prostatectomy 2 (0, 6) 41.9 (12.6) 93 (83, 100)
  External beam radiation therapy 1 (0, 4) 42.4 (13.5) 97 (83, 100)
  Brachytherapy 0 (0, 3) 43.0 (15.0) 90 (83, 100)
Planned neoadjuvant hormonal therapy 0.97 0.63 0.84
  No 1 (0, 5) 42.2 (13.5) 93 (83, 100)
  Yes 2 (0, 4) 43.3 (13.1) 93 (83, 100)
 A higher score refl ects an increase in perceived danger, uncertainty and satisfaction with treatment outcome.  * Spearman rank correlation coeffi cient  P values 
(vs. correlation of 0) as specifi ed in the Table. Because of sparse cell values,  ‘ Race/Ethnicity ’ and  ‘ Married or with partner ’ were compared using the Kruskall –
 Wallis test. The remaining  P values were obtained from univariate GEE models of the demographic on perception of danger, uncertainty and satisfaction with 
treatment outcome.  † Only one participant did not report  ‘ Married or with partner ’ status and no  SD was calculated. 
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responses to danger and satisfaction of 
outcome were heavily skewed, the median 
and fi rst and third quartile are shown 
in  Table  2 . Uncertainty responses were 
more closely distributed; these data are 
presented as mean ( SD ) values. Each test 
was two-sided and a  P value of 0.05 was 
considered to indicate statistical 
signifi cance. Univariate characteristics 
signifi cantly associated with each outcome 
were tested in a multivariable linear 
regression model, again using GEEs, to see 
if their association remained ( Table  3A 
and B ). Spearman rank correlations were 
used to assess the general trend among 
perception of danger, uncertainty, and 
satisfaction with treatment outcome 
domains ( Table  4 ). 
 RESULTS 
 Among the 338 patients who consented, 
328 patients completed the interview 
suffi ciently so as to be included in the 
analysis.  Table  1 shows the characteristics of 
these 328 patients, the 10 patients who 
consented but did not suffi ciently complete 
the interviews, and the 106 patients who 
declined to participate. Characteristics of 
men in the PROSTQA study cohort who were 
approached to participate in the present 
study were not signifi cantly different among 
those who agreed or declined to participate 
( Table  1 ), with the exception that patients 
with clinical stage T2 disease were more 
likely to consent than those with T1 disease 
( P  = 0.004). 
 Among the 328 analysable participants, the 
median danger score was 1/5 (interquartile 
range  [ IQR ] 0, 4), the mean uncertainty 
score was 42.3/75 ( SD 13.4), and the median 
satisfaction with treatment outcome score 
was 93/100 (IQR 83, 100). There was a 
signifi cant association among each of these 
domains ( Table  4 ): Perception of danger 
was positively correlated with uncertainty 
( r  = 0.34,  P  < 0.001) and negatively 
correlated with satisfaction with treatment 
outcome ( r  =  − 0.30,  P  < 0.001), and 
uncertainty was likewise negatively 
correlated with satisfaction with treatment 
outcome ( r  =  − 0.33,  P  < 0.001). 
 Table  2 shows the associations of patient 
characteristics with perception of danger, 
uncertainty and satisfaction with treatment 
outcome. Younger patients appeared to 
perceive a greater degree of danger than 
older patients ( r  =  − 0.12,  P  = 0.03). Younger 
patients were also more likely to report a 
lower degree of uncertainty than older 
patients ( r  = 0.20,  P  < 0.001). African-
American patients also reported greater 
uncertainty than other ethnic groups (mean 
 [ SD ] score 51.7  [ 13.6 ] ,  P  = 0.005). Similarly, 
level of education appeared to be associated 
with the experience of uncertainty, such 
that patients with lower levels of education 
were more likely to report a higher degree 
of uncertainty than those with either a 
college or graduate-level degree ( r  =  − 0.25; 
 P  < 0.001). Planned treatment showed a 
marginal association with perception of 
 TABLE  3  Multivariable associations with  A , perception of danger and  B , uncertainty among the 328 
patients 
Characteristic Coeffi cient ( SE )  P * 
A: Multivariable associations with perception of danger
  Intercept 1.6 (3.2)  – 
  Planned treatment 0.01
   Radical prostatectomy 10.8 (4.9)
   External beam radiation therapy  − 4.5 (4.5)
   Brachytherapy Reference
  Age at planned treatment † 0.02
   Radical prostatectomy  − 0.13 (0.06)
   External beam radiation th  erapy 0.09 (0.05)
   Brachytherapy 0.01 (0.05)
B: Multivariable associations with uncertainty
  Intercept 16.1 (8.3)  – 
  Age at treatment 0.4 (0.1)  < 0.001
  Race/Ethnicity 0.05
   White  − 0.4 (5.4)
  African-American 7.6 (5.9)
   Other 2.0 (6.2)
   Not reported Reference
  Base education level at treatment 0.001
   < High school graduate 9.5 (2.5)
   High school graduate 7.2 (2.1)
   Some college education 5.4 (1.9)
   College graduate 2.7 (1.9)
   Graduation school Reference
 A higher score refl ects an increase in perceived danger and uncertainty.  * Multivariable associations 
were tested using Wald tests from linear regression (using GEEs). Characteristics with a signifi cant 
univariate association were included for danger and uncertainty.  † The  ‘ age at treatment ’ main effect 
was included in the multivariable danger model ( P  = 0.77) and is accounted for in estimating the  ‘ Age 
at planned treatment ’ coeffi cients and  SE s. 




Danger  – 0.34  − 0.30
 P  < 0.001  P  < 0.001
Uncertainty  –  − 0.33
 P  < 0.001
Satisfaction with treatment outcome  – 
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danger ( P  = 0.05) and satisfaction of 
treatment outcome ( P  = 0.05). 
 The associations of age, race and education 
with uncertainty remained when considered 
in a multivariable model ( Table  3A and B ). As 
for perception of danger, the association of 
age and treatment remained, but age was 
modifi ed by treatment group. Younger 
patients were associated with a greater 
danger score among those receiving radical 
prostatectomy  – the youngest treatment 
group with a median age of 61 years; 
however, the association of younger age and 
greater perception of danger did not remain 
within the patients undergoing external 
beam radiation therapy (median age 69 
years). 
 DISCUSSION 
 The present study extends the previous 
understanding of prostate cancer survivors ’ 
uncertainty and their perception of danger 
regarding prostate cancer, by evaluating the 
impact of these factors on satisfaction with 
overall prostate cancer treatment outcome. 
Previous researchers have identifi ed an 
association between age, race/ethnicity, 
education, medical comorbidity and illness 
uncertainty in prostate cancer  [ 7,9,15 ] but 
how these concerns relate to cancer 
survivors ’ satisfaction with overall cancer 
care outcome has not previously been 
characterized. 
 African-American patients reported higher 
levels of uncertainty compared with other 
ethnic groups. This fi nding is consistent with 
the work of Germino  et  al.  [ 7 ] , who 
evaluated the role of uncertainty in 
determining quality of life in men with 
localized prostate cancer. The researchers 
in the present study reported marked 
differences in uncertainty scores related to 
race. The fi ndings from the present and 
previous studies may be explained by the 
higher probability of dying from prostate 
cancer in the African-American ethnic 
group  [ 1 ] . Moreover, a traditional lack of 
trust in the healthcare system among 
African-American men, as described by 
Halbert  et  al.  [ 16 ] , may have contributed to 
the higher level of uncertainty among 
African-American men with prostate 
cancer regarding their disease and the 
side effects of its treatment. The 
combination of the aggressiveness of 
tumours in this ethnic group and the lack of 
trust in healthcare providers to effectively 
manage recurrent disease may have led to 
this uncertainty. 
 In the univariate setting, the present 
study found that a higher degree of 
perceived danger was associated with 
surgery; multivariable analysis, however, 
indicates that this association may be 
driven by treatment method  or by age. 
These fi ndings are consistent with the 
report by Germino  et  al .  [ 7 ] who found that 
there were no differences in uncertainty 
between the radical prostatectomy group 
and the radiation treatment group. The 
authors did observe low, but signifi cant 
correlations between uncertainty and 
coping, psychological adjustment, and 
perceptions of health and illness. 
Furthermore, uncertainty was not related 
to perceptions about quality of care or 
treatment. 
 As hypothesized, greater uncertainty was 
associated with greater danger and a 
reduction in satisfaction with treatment 
outcome. This fi nding may have important 
implications for the role of uncertainty and 
danger management in improving patient 
satisfaction with treatment by managing the 
perception of uncertainty and danger 
associated with diagnosis. Interestingly, the 
correlation of uncertainty with outcome 
satisfaction that was observed ( r  =  − 0.33) 
was stronger than correlation of health-
related quality-of-life domains with overall 
cancer care outcome satisfaction (whose 
correlation  r was generally  < 0.3) as 
previously reported by Sanda  et  al.  [ 5 ] , 
suggesting that cancer survivor uncertainty 
and perception of danger warrant greater 
emphasis in medical decision-making and in 
the education of patients with newly 
diagnosed prostate cancer and treated 
survivors alike. 
 The present study showed that as 
uncertainty and perceived danger increase, 
patient satisfaction with treatment 
decreases. Hart  et  al.  [ 17 ] reported that, in 
the CaPSURE cohort, treatment satisfaction 
levels mitigated the impact of fear of 
recurrence on lower levels of quality of life. 
Specifi cally, men who reported lower 
treatment satisfaction and fear of 
recurrence reported signifi cantly lower levels 
of quality of life compared with other 
patients in the sample. Interventions that 
reduce uncertainty and manage perceptions 
of danger, such as those reported by Kazer 
 et  al.  [ 18 ] may potentially improve both 
quality of life and satisfaction with 
treatment outcome. 
 Whereas previous studies have been 
small and have focused on the period 
immediately after treatment when studying 
uncertainty and danger, a strength of the 
present study is that it draws from a large 
cohort of men from multiple sites across the 
USA followed up for 4 – 6 years after 
treatment for prostate cancer. This cohort 
provided a means of studying the impact of 
uncertainty and danger on satisfaction of 
prostate cancer treatment outcome. The 
results of the present study provide 
information that health professionals can 
use in patient education and in helping 
improve patient outcomes after treatment. 
Furthermore, the fi ndings can be used as the 
basis for the design and implementation of 
future uncertainty management 
interventions for patients with prostate 
cancer. 
 A limitation of the present study was the 
fact that, as a companion study to an 
ongoing longitudinal cohort, data collection 
was initiated at 48 – 72 months after 
treatment and therefore uncertainty and 
danger baseline data before initiation of 
treatment, and at the time of diagnosis are 
lacking. However, as the parent study 
provides access to a large number of 
men treated for prostate cancer, and 
because of the limited amount of 
information available on the impact of 
uncertainty and danger appraisal on 
satisfaction with prostate cancer treatment 
outcome, it is felt that the present study can 
add substantially to the body of knowledge 
in the area. In addition, by conducting the 
study in conjunction with the larger parent 
study, data were available for the two 
studies with little additional expense, which 
is an effi cient use of available research 
funds. 
 In conclusion, uncertainty and perception of 
danger among men with prostate cancer 
correlate negatively with satisfaction with 
outcome of therapy. Age, race and education 
all appear to be associated with these 
outcomes to varying degrees. Cancer 
survivor uncertainty and perception of 
danger warrant greater emphasis in medical 
decision-making and in the education of 
patients with newly diagnosed prostate 
P R O S T A T E  C A N C E R  T R E A T M E N T  A N D  U N C E R T A I N T Y / P E R C E P T I O N  O F  D A N G E R
©  2 0 1 2  T H E  A U T H O R S
B J U  I N T E R N A T I O N A L  ©  2 0 1 2  B J U  I N T E R N A T I O N A L  E 9 1
cancer and treated survivors alike. This 
unmet health need is a rational target for 
future expansion of nursing care. The results 
of the present study strengthen support 
for the development of uncertainty 
management interventions to improve 
patient outcomes. Improved uncertainty 
management has the potential to facilitate 
higher quality of life and satisfaction with 
treatment outcome among the large number 
of patients with prostate cancer undergoing 
all treatment options. 
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